Efficacy and tolerability of valproate versus topiramate in migraine prevention, a randomized controlled multi-center trial
Abstract
Although topiramate and valproate are antiseizure medications that have many contraindications and could produce many side effects, they are still used as migraine preventive therapy in middle- and low-income countries. Several trials compared valproate versus topiramate in patients with migraine showed inconclusive results. We aimed to evaluate the tolerability and efficacy of valproate compared to topiramate in migraineurs from the Middle East and North Africa. Our single-blinded, multi-centre, randomized controlled trial had two parallel groups: the (A) group, which included 300 patients who received valproate, and the (B) group, which included 300 patients who received topiramate. In our trial, 574 patients completed the 3-month follow-up period. Topiramate achieved a greater reduction in migraine attack severity on VAS and HIT-6 than valproate to a degree that was statistically significant. 129 (43 %) patients in valproate group and 66 (22 %) in topiramate group had any adverse effects (HR 3.11; 95 % CI 1.08-6.13; P = 0.05), of which 23 patients (7.7 %) in valproate group and twelve patients (4 %) in the topiramate group stopped treatment prematurely due to intolerable adverse effects (HR 2.47; 95 % CI 1.04-5.88; P = 0.04). We concluded that, in adult patients with migraine, the regular use of topiramate 50 mg Bid for three months yielded significantly higher reductions in migraine attack severity and HIT6 score compared to using valproate 500 mg Bid; valproate led to a…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 574 participants or records.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.